Key Metrics

Market Cap
Total Shares Outstanding
Book Value
PE Ratio

PS Ratio
PB Ratio
Forward PE Ratio
ROIC

Return on Aseets
Return on Equity
Dividend
Dividend Yield

Balancesheet Metrics

Total Assets	107.34M
Total Liability	5.86M
Assets-to-Libability Ratio	18.32

Total Current Assets	107.34M
Total Current Liability	5.86M
Current Ratio	18.32

Quick Ratio	-
Debt to Equity Ratio	-

Income Statement Metrics

Net Income
EPS
EBITA

Gross Profit
Gross Profit Margin
Operating Margin

Net Profit Margin

Price Metrics

5 Days MA
10 Days MA
20 Days MA
50 Days MA
200 Days MA

52 Weeks High
52 Weeks low
All Time High

RSI
MACD

Share Stats

Shares Float
Shares Short

% Short
% Insider

% Institutions

% Institutions

News

Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business CombinationTaipei City, Jan. 13, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) (the “Company”) announced today that its sponsor, MP One Investment LLC (the “Sponsor”) and Apollomics Inc. (“Apollomics”), deposited additional payments in the aggregate amount of $1...
Taipei City, Jan. 13, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) (the “Company”) announced today that its sponsor, MP One Investment LLC (the “Sponsor”) and Apollomics Inc. (“Apollomics”), deposited additional payments in the aggregate amount of $1,035,000 (representing $0.10 per public share) (the “Extension Payment”) into the Company’s trust account for its public stockholders. This deposit enables the Company to extend the date by which the Company has to complete its initial business combination from January 13, 2023 to April 13, 2023 (the “Extension”). The Extension is the second of two three-month extensions permitted under the Company’s governing documents. The Extension provides the Company with additional time to complete its initial business combination with Apollomics, previously announced by the Company and Apollomics on September 14, 2022. The Sponsor and Apollomics each loaned half of the Extension Payment to the Company. The Sponsor’s half of the loan is convertible at the Sponsor’s discretion into units identical to the units issued in the Company’s private placement that was consummated in connection with the Company’s initial public offering. About Maxpro Capital Acquisition Corp. Maxpro is a blank check company formed for the purposes of effecting a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the healthcare and technology industries. In October 2021, Maxpro consummated a $103.5 million initial public offering of 10.35 million units (including the underwriters’ full exercise of their over-allotment option), with each unit consisting of one share of Class A common stock and one redeemable warrant, and each warrant entitling the holder to purchase one share of Class A common stock at a price of $11.50 per share. On November 26, 2021, Maxpro announced that holders of its units could elect to separately trade the shares of Class A common stock and redeemable warrants included in the units. EF Hutton, division of Benchmark Investments LLC, served as the sole book-running manager of Maxpro’s initial public offering. About Apollomics Inc. Apollomics is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics currently has a pipeline of nine drug candidates across multiple programs, six of which are currently in the clinical stage of development. Apollomics’ lead programs include investigating its core product, vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States, and developing an anti-cancer enhancer drug candidate, uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia and other hematologic cancers, which is currently in Phase 1 and Phase 3 clinical trials in China. FORWARD-LOOKING STATEMENTS This press release may include, and oral statements made from time to time by representatives of the Company may include, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding possible business combinations and the financing thereof, and related matters, as well as all other statements other than statements of historical fact included in this press release are forward-looking statements. When used in this press release, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions, as they relate to us or our management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company’s filings with the Securities and Exchange Commission (the “SEC”). All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and prospectus for the Company’s initial public offering filed with the SEC, the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, the Company’s Quarterly Reports on Form 10-Q and other filings with the SEC. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. Contact Maxpro Capital Acquisition Corp. Songren Road, Xinyi District Taipei City 11073 Attn: Moses Chen Chief Executive Officer m.chen@maxproventures.com +886 2 7713 7952
JMAC JMACU JMACW | globenewswire | about 3 years ago | Neutral

Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business CombinationTAIPEI CITY, Jan. 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) (the “Company”), announced today that its sponsor, MP One Investment LLC (the “Sponsor”), has requested that the Company extend the date by which the Company has to consummate a busine...
TAIPEI CITY, Jan. 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) (the “Company”), announced today that its sponsor, MP One Investment LLC (the “Sponsor”), has requested that the Company extend the date by which the Company has to consummate a business combination from January 13, 2023 to April 13, 2023 (the “Extension”). The Extension is the second of two three-month extensions permitted under the Company’s governing documents. In connection with the Extension, the Sponsor and Apollomics Inc. (“Apollomics”) have notified the Company that they intend to bear the cost of the Extension in the aggregate amount of $1,035,000 (representing $0.10 per public share) and such funds will be deposited into the Company’s trust account on or before January 13, 2022. The Extension provides the Company with additional time to complete its initial business combination with Apollomics, previously announced by the Company and Apollomics on September 14, 2022. About Maxpro Capital Acquisition Corp. Maxpro is a blank check company formed for the purposes of effecting a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the healthcare and technology industries. In October 2021, Maxpro consummated a $103.5 million initial public offering of 10.35 million units (including the underwriters’ full exercise of their over-allotment option), with each unit consisting of one share of Class A common stock and one redeemable warrant, and each warrant entitling the holder to purchase one share of Class A common stock at a price of $11.50 per share. On November 26, 2021, Maxpro announced that holders of its units could elect to separately trade the shares of Class A common stock and redeemable warrants included in the units. EF Hutton, division of Benchmark Investments LLC, served as the sole book-running manager of Maxpro’s initial public offering. About Apollomics Inc. Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics currently has a pipeline of nine drug candidates across multiple programs, six of which are currently in the clinical stage of development. Apollomics’ lead programs include investigating its core product, vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States, and developing an anti-cancer enhancer drug candidate, uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia and other hematologic cancers, which is currently in Phase 1 and Phase 3 clinical trials in China. FORWARD-LOOKING STATEMENTS This press release may include, and oral statements made from time to time by representatives of the Company may include, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding possible business combinations and the financing thereof, and related matters, as well as all other statements other than statements of historical fact included in this press release are forward-looking statements. When used in this press release, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions, as they relate to us or our management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company’s filings with the Securities and Exchange Commission (“SEC”). All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and prospectus for the Company’s initial public offering filed with the SEC, the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, the Company’s Quarterly Reports on Form 10-Q and other filings with the SEC. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. Contact Maxpro Capital Acquisition Corp. Songren Road, Xinyi District Taipei City 11073 Attn: Moses Chen Chief Executive Officer m.chen@maxproventures.com +886 2 7713 7952
JMAC JMACU JMACW | globenewswire | about 3 years ago | Neutral

Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business CombinationTAIPEI CITY, Oct. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) (the “Company”) announced today that its sponsor, MP One Investment LLC (the “Sponsor”), deposited an additional payment in the aggregate amount of $1,035,000 (representing $0.10 per p...
TAIPEI CITY, Oct. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) (the “Company”) announced today that its sponsor, MP One Investment LLC (the “Sponsor”), deposited an additional payment in the aggregate amount of $1,035,000 (representing $0.10 per public share) (the “Extension Payment”) into the Company’s trust account for its public stockholders. This deposit enables the Company to extend the date by which the Company has to complete its initial business combination from October 13, 2022 to January 13, 2023 (the “Extension”). The Extension is the first of two three-month extensions permitted under the Company’s governing documents. The Extension provides the Company with additional time to complete its initial business combination with Apollomics Inc. (“Apollomics”), previously announced by the Company and Apollomics on September 14, 2022. The Sponsor loaned the Extension Payment to the Company, which loan is convertible, at the Sponsor’s discretion, into units identical to the units issued in the Company’s private placement that was consummated in connection with the Company’s initial public offering. About Maxpro Capital Acquisition Corp. Maxpro is a blank check company formed for the purposes of effecting a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the healthcare and technology industries. In October 2021, Maxpro consummated a $103.5 million initial public offering of 10.35 million units (including the underwriters’ full exercise of their over-allotment option), with each unit consisting of one share of Class A common stock and one redeemable warrant, and each warrant entitling the holder to purchase one share of Class A common stock at a price of $11.50 per share. On November 26, 2021, Maxpro announced that holders of its units could elect to separately trade the shares of Class A common stock and redeemable warrants included in the units. EF Hutton, division of Benchmark Investments LLC, served as the sole book-running manager of Maxpro’s initial public offering. About Apollomics Inc. Apollomics is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics currently has a pipeline of nine drug candidates across multiple programs, six of which are currently in the clinical stage of development. Apollomics’ lead programs include investigating its core product, vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States, and developing an anti-cancer enhancer drug candidate, uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia and other hematologic cancers, which is currently in Phase 1 and Phase 3 clinical trials in China. FORWARD-LOOKING STATEMENTS This press release may include, and oral statements made from time to time by representatives of the Company may include, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding possible business combinations and the financing thereof, and related matters, as well as all other statements other than statements of historical fact included in this press release are forward-looking statements. When used in this press release, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions, as they relate to us or our management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company’s filings with the Securities and Exchange Commission (the “SEC”). All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and prospectus for the Company’s initial public offering filed with the SEC, the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, the Company’s Quarterly Reports on Form 10-Q and other filings with the SEC. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. Contact Maxpro Capital Acquisition Corp. Songren Road, Xinyi District Taipei City 11073 Attn: Moses Chen Chief Executive Officer m.chen@maxproventures.com +886 2 7713 7952
JMAC JMACU JMACW | globenewswire | about 3 years ago | Neutral

Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business CombinationTaipei City, Oct. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) (the “Company”), announced today that its sponsor, MP One Investment LLC (the “Sponsor”), has requested that the Company extend the date by which the Company has to consummate a busin...
Taipei City, Oct. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) (the “Company”), announced today that its sponsor, MP One Investment LLC (the “Sponsor”), has requested that the Company extend the date by which the Company has to consummate a business combination from October 13, 2022 to January 13, 2023 (the “Extension”). The Extension is the first of two three-month extensions permitted under the Company’s governing documents. In connection with the Extension, the Sponsor has notified the Company that it intends to deposit an aggregate of $1,035,000 (representing $0.10 per public share) into the Company’s trust account on or before October 13, 2022. The Extension provides the Company with additional time to complete its initial business combination with Apollomics Inc. (“Apollomics”), previously announced by the Company and Apollomics on September 14, 2022. About Maxpro Capital Acquisition Corp. Maxpro is a blank check company formed for the purposes of effecting a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the healthcare and technology industries. In October 2021, Maxpro consummated a $103.5 million initial public offering of 10.35 million units (including the underwriters’ full exercise of their over-allotment option), with each unit consisting of one share of Class A common stock and one redeemable warrant, and each warrant entitling the holder to purchase one share of Class A common stock at a price of $11.50 per share. On November 26, 2021, Maxpro announced that holders of its units could elect to separately trade the shares of Class A common stock and redeemable warrants included in the units. EF Hutton, division of Benchmark Investments LLC, served as the sole book-running manager of Maxpro’s initial public offering. About Apollomics Inc. Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics currently has a pipeline of nine drug candidates across multiple programs, six of which are currently in the clinical stage of development. Apollomics’ lead programs include investigating its core product, vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States, and developing an anti-cancer enhancer drug candidate, uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia and other hematologic cancers, which is currently in Phase 1 and Phase 3 clinical trials in China. FORWARD-LOOKING STATEMENTS This press release may include, and oral statements made from time to time by representatives of the Company may include, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding possible business combinations and the financing thereof, and related matters, as well as all other statements other than statements of historical fact included in this press release are forward-looking statements. When used in this press release, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions, as they relate to us or our management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company’s filings with the Securities and Exchange Commission (“SEC”). All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and prospectus for the Company’s initial public offering filed with the SEC, the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, the Company’s Quarterly Reports on Form 10-Q and other filings with the SEC. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. Contact Maxpro Capital Acquisition Corp. Songren Road, Xinyi District Taipei City 11073 Attn: Moses Chen Chief Executive Officer m.chen@maxproventures.com +886 2 7713 7952
JMAC JMACU JMACW | globenewswire | about 3 years ago | Neutral

Maxpro Capital Acquisition Corp. Announces the Separate Trading of Its Class A Common Stock and WarrantsTAIPEI CITY, Nov. 26, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Maxpro Capital Acquisition Corp. (“Maxpro” or the “Company”), a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combina...
TAIPEI CITY, Nov. 26, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Maxpro Capital Acquisition Corp. (“Maxpro” or the “Company”), a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, today announced that holders of the units sold in the Company’s initial public offering of 10,350,000 units completed on October 13, 2021, may elect to separately trade the shares of Class A common stock and warrants included in the units commencing on or about November 26, 2021. Holders of units will need to have their broker contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the units into shares of Class A common stock and warrants. Those units not separated will continue to trade on the Nasdaq Global Market (“Nasdaq”) under the ticker symbol “JMACU,” and the Class A common stock and warrants that are separated will trade on Nasdaq under the symbols “JMAC” and “JMACW,” respectively. The securities described above were offered by the Company pursuant to a registration statement on Form S-1 (File No. 333-258091) that was originally filed with the Securities and Exchange Commission (“SEC”) on July 22, 2021 and declared effective on October 7, 2021. The offering was made only by means of a prospectus, copies of which may be obtained from: EF Hutton, division of Benchmark Investments, LLC, 590 Madison Ave, 39thFloor, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@efhuttongroup.com or telephone at (212) 404-7002, or by visiting EDGAR on the SEC’s website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Forward-Looking Statements This press release contains statements that constitute "forward-looking statements," including with respect to the Company's initial public offering and search for an initial business combination. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based, except as required by law. Contact Maxpro Capital Acquisition Corp. Songren Road, Xinyi District Taipei City 11073 Attn: Moses Chen Chief Executive Officer m.chen@maxproventures.com +886 2 7713 7952
JMAC JMACU JMACW | globenewswire | about 4 years ago | Neutral

Maxpro Capital Acquisition Corp. Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment OptionTaipei City, Oct. 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Maxpro Capital Acquisition Corp. (the “Company”), a Taiwan based SPAC, today announced the closing of its initial public offering (the “Offering”) of 9,000,000 units at $10.00 per unit. Each unit consists of one share of Class A co...
Taipei City, Oct. 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Maxpro Capital Acquisition Corp. (the “Company”), a Taiwan based SPAC, today announced the closing of its initial public offering (the “Offering”) of 9,000,000 units at $10.00 per unit. Each unit consists of one share of Class A common stock and one redeemable warrant. The underwriters exercised their over-allotment option in full for an additional 1,350,000 units at the time of the closing of the Offering. As a result, the aggregate gross proceeds of the Offering, including the over-allotment, is approximately $103.5 million, prior to deducting underwriting discounts, commissions, and other Offering expenses. The Company is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any business or industry, it intends to focus on industries that complement its management team’s background and to capitalize on the ability of the management team to identify and acquire a business where the management team has extensive experience. Sectors the Company plans on exploring include, but are not limited to, the healthcare and technology industries, specifically within the biotechnology and pharmaceutical sectors. The Company is sponsored by an affiliate of Maxpro Ventures Ltd., a respected Taiwan based venture capital firm specialized in the healthcare industry. EF Hutton, division of Benchmark Investments, LLC, acted as sole book running manager for the offering. The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from EF Hutton, division of Benchmark Investments LLC, Attn: Syndicate Department, 590 Madison Ave., 39th Floor, New York, New York 10022, by telephone at (212) 404-7002, by fax at (646) 861-4697, or by email at syndicate@efhuttongroup.com. A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission on October 7, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. FORWARD-LOOKING STATEMENTS This press release contains statements that constitute “forward-looking statements,” including with respect to the initial public offering and the anticipated use of the net proceeds. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and preliminary prospectus for the offering filed with the Securities and Exchange Commission (“SEC”). Copies are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. Contact Maxpro Capital Acquisition Corp. 5/F-4, No. 89 Songren Road, Xinyi District Taipei City 11073 Attn: Moses Chen Chief Executive Officer m.chen@maxproventures.com +886 2 7713 7952
JMAC JMACU JMACW | globenewswire | about 4 years ago | Neutral

Maxpro Capital Acquisition Corp. Announces Pricing of $90,000,000 Initial Public OfferingTaipei City, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Maxpro Capital Acquisition Corp. (the “Company”), a Taiwan based SPAC, announced today that it priced its initial public offering of $90 million, consisting of 9,000,000 units at $10.00 per unit. The units will be listed on the Nas...
Taipei City, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Maxpro Capital Acquisition Corp. (the “Company”), a Taiwan based SPAC, announced today that it priced its initial public offering of $90 million, consisting of 9,000,000 units at $10.00 per unit. The units will be listed on the Nasdaq Global Market (“Nasdaq”) and will begin trading tomorrow, Friday, October 8th, 2021, under the ticker symbol “JMACU”. Each unit consists of one share of the Company’s Class A common stock and one redeemable warrant entitling the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share. Only whole warrants are exercisable. Once the securities comprising the units begin separate trading, the shares of Class A common stock and warrants are expected to be listed on Nasdaq under the symbols “JMAC” and “JMACW,” respectively. The Company is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any business or industry, it intends to focus on industries that complement its management team’s background and to capitalize on the ability of the management team to identify and acquire a business where the management team has extensive experience. Sectors the Company plans on exploring include, but are not limited to, the healthcare and technology industries, specifically within the biotechnology and pharmaceutical sectors. The Company is sponsored by an affiliate of Maxpro Ventures Ltd., a respected Taiwan based venture capital firm specialized in the healthcare industry. EF Hutton, division of Benchmark Investments, LLC, is acting as sole book running manager for the offering. The Company has granted the underwriter a 45-day option to purchase up to an additional 1,350,000 units at the initial public offering price to cover over-allotments, if any. The offering is being made only by means of a prospectus. Copies of the prospectus may be obtained, when available, from EF Hutton, division of Benchmark Investments LLC, Attn: Syndicate Department, 590 Madison Ave., 39th Floor, New York, New York 10022, by telephone at (212) 404-7002, by fax at (646) 861-4697, or by email at syndicate@efhuttongroup.com. A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission on October 7, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. FORWARD-LOOKING STATEMENTS This press release contains statements that constitute “forward-looking statements,” including with respect to the initial public offering and the anticipated use of the net proceeds. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and preliminary prospectus for the offering filed with the Securities and Exchange Commission (“SEC”). Copies are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. Contact Maxpro Capital Acquisition Corp. 5/F-4, No. 89 Songren Road, Xinyi District Taipei City 11073 Attn: Moses Chen Chief Executive Officer m.chen@maxproventures.com +886 2 7713 7952
JMAC JMACU JMACW | globenewswire | about 4 years ago | Neutral

Profile

Maxpro Capital Acquisition Corp Unit (JMACU)

Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.

Exchange: NASDAQ

IPO Date: 10/8/2021

Sector: Financial Services

Industry: Shell Companies

Employees: 0

Address: No. 89 Songren Road, Taipei, Taiwan, 11073

https://www.maxproventures.com

Quarterly Yearly

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	12/31/2022	09/30/2022	06/30/2022	03/31/2022	12/31/2021	09/30/2021	06/30/2021	Totals
	12/31/2022	09/30/2022	06/30/2022	03/31/2022	12/31/2021	09/30/2021	06/30/2021	Totals
Assets	107.34K	105.88K	105.56K	105.48K	105.81K	288.287	138.335	530.50K
Current Assets	107.34K	105.88K	370.673	383.255	752.943	16.847	55.285	214.80K
Cash And Short Term Investments	69.107	134.11	279.269	301.946	598.957	-	-	1.38K
Net Receivables	-	-	-	-	-	-	-	-
Inventory	-	-	-	-	-	-	-	-
Other Current Assets	107.27K	105.75K	91.404	81.309	153.986	-	-	213.34K
Non Current Assets	-	-	105.19K	105.09K	105.06K	271.44	83.05	315.70K
Property Plant Equipment	-	-	-	-	-	-	-	-
Long Term Investments	-	-	-	-	-	-	-	-
Non Currrent Assets Other	-	-	105.19K	105.09K	-	-	-	210.29K
Liabilities	5.86K	4.38K	4.00K	3.68K	3.66K	269.115	114.78	21.95K
Current Liabilities	5.86K	4.38K	376.162	53.873	34.195	269.115	114.78	11.08K
Accounts Payable	806.026	755.529	376.162	53.873	-	1.43	-	1.99K
Short Long Term Debt	-	-	-	-	-	108.666	30.3	138.966
Other Current Liabilities	5.05K	4.38K	376.162	53.873	34.195	-	-	9.89K
Non Current Liabilities	806.026	-	3.62K	3.62K	3.62K	-	-	11.67K
Long Term Debt	-	-	-	-	-	-	-	-
Other Liabilities	-	-	-	-	-	-	-	-
Stockholder Equity	-5.54K	101.51K	101.56K	101.80K	-2.90K	19.172	23.555	296.48K
Preferred Stock Equity	-	-	-	-	-	-	-	-
Liabilities And Stockholders Equity	107.34K	105.88K	105.56K	105.48K	761.129	-	-	425.02K
Common Equity	-	-	-	-	-	-	-	-
Retained Earnings	-	-	-	-	-	-	-	-
Totals		442.19K	538.93K	532.56K	531.17K	217.59K	1.24K	560.0849999999999	2.26M

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	12/31/2022	12/31/2021	Totals
	12/31/2022	12/31/2021	Totals
Assets	107.34K	105.81K	213.15K
Current Assets	107.34K	752.943	108.09K
Cash And Short Term Investments	69.107	598.957	668.064
Other Current Assets	107.27K	153.986	107.42K
Non Current Assets	-	105.06K	105.06K
Non Currrent Assets Other	-	105.06K	105.06K
Liabilities	5.86K	3.66K	9.52K
Current Liabilities	5.86K	34.195	5.89K
Accounts Payable	806.026	-	806.026
Other Current Liabilities	5.05K	34.195	5.09K
Non Current Liabilities	806.026	3.62K	4.43K
Stockholder Equity	-5.54K	-2.90K	-8.44K
Liabilities And Stockholders Equity	107.34K	761.129	108.10K
Totals		442.19K	322.65K	764.85K

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	06/30/2022	03/31/2022	12/31/2021	09/30/2021	Totals
	06/30/2022	03/31/2022	12/31/2021	09/30/2021	Totals
Revenue	-	-	-	-	-
Cost Of Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
Operating Expenses	383.854	389.366	185.572	4.383	963.1750000000001
Selling General Administrative	383.854	389.366	185.572	4.383	963.1750000000001
Research Development	-	-	-	-	-
Other Operating Expenses	383.854	389.366	185.572	-	958.792
Operating Income	-383.854	-389.366	-	-4.383	-777.6030000000001
Net Interest Income	146.864	33.402	-	-	180.26600000000002
Interest Income	146.864	33.402	-	-	180.26600000000002
Interest Expense	146.864	33.402	-	-	180.26600000000002
Other Income Expense Net	146.864	33.402	-	-	180.26600000000002
Income Before Tax	-236.99	-355.964	-177.386	-4.383	-774.723
Tax Provision	-	-	-	-	-
NetIncome	-236.99	-355.964	-177.386	-4.383	-774.723
NetIncome Applicable To Common Shares	-	-	-	-	-
Ebit	-	-	-	-	-
Totals		881.184	200.4120000000002	201.94400000000005	-4.383	1.28K

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	12/31/2021	Totals
	12/31/2021	Totals
Revenue	-	-
Cost Of Revenue	-	-
Gross Profit	-	-
Operating Expenses	185.572	185.572
Selling General Administrative	185.572	185.572
Research Development	-	-
Other Operating Expenses	185.572	185.572
Operating Income	-	-
Net Interest Income	-	-
Interest Income	-	-
Interest Expense	-	-
Other Income Expense Net	-	-
Income Before Tax	-177.386	-177.386
Tax Provision	-	-
NetIncome	-177.386	-177.386
NetIncome Applicable To Common Shares	-	-
Ebit	-	-
Totals		201.94400000000005	201.94400000000005

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	12/31/2022	09/30/2022	06/30/2022	03/31/2022	12/31/2021	09/30/2021	Totals
	12/31/2022	09/30/2022	06/30/2022	03/31/2022	12/31/2021	09/30/2021	Totals
Cash From Operating Activities	-733.674	-145.159	-71.66	-297.011	-305.363	-	-1.55K
Net Income	-618.831	-58.652	-236.99	-355.964	-177.386	-4.383	-1.45K
Depreciation	-	-	-	-	-	-	-
Extraordinary Items	-	-	-	-	-	-	-
Change Receivables	-	-	-	-	-	-	-
Change To Inventory	-	-	-	-	-	-	-
Change To Liabilities	-	-	-	-	-	-	-
Change To Net Income	-	-	-	-	-	-	-
ChangeToOperatingActivities	-	-	-	-	-	-	-
Cash flows From Investing Activities	-	-	-	-	-	-	-
Capital Expenditures	-	-	-	-	-	-	-
Other Cashflows From Investing Activities	-	-	-	-	-	-	-
Cash From Financing Activities	1.33K	-	-	-	105.96K	-	107.29K
Net Borrowings	-	-	-	-	-	-	-
Sale Purchase Of Stock	-	-	-	-	-	-	-
Dividends Paid	-	-	-	-	-	-	-
Other Cashflows From Financing Activities	1.33K	-	48.983	-	105.96K	-	107.34K
Cash And Cash Equivalents Changes	-	-	-	-	-	-	-
Totals		1.32K	-203.81099999999998	-259.667	-652.975	211.43K	-4.383	211.63K

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	12/31/2022	12/31/2021	Totals
	12/31/2022	12/31/2021	Totals
Cash From Operating Activities	-878.833	-305.363	-1.18K
Net Income	-677.483	-177.386	-854.8689999999999
Depreciation	-	-	-
Extraordinary Items	-	-	-
Change Receivables	-	-	-
Change To Inventory	-	-	-
Change To Liabilities	-	-	-
Change To Net Income	-	-	-
ChangeToOperatingActivities	-	-	-
Cash flows From Investing Activities	-	-	-
Capital Expenditures	-	-	-
Other Cashflows From Investing Activities	-	-	-
Cash From Financing Activities	1.33K	105.96K	107.29K
Net Borrowings	-	-	-
Sale Purchase Of Stock	-	-	-
Dividends Paid	-	-	-
Other Cashflows From Financing Activities	1.33K	105.96K	107.29K
Cash And Cash Equivalents Changes	-	-	-
Totals		1.11K	211.43K	212.54K

Profile

Free Stocks

Company

Features

Contact Us